Display options
Cite
Hong X, Qin J, Li T, et al. Staphylococcal Protein A Promotes Colonization and Immune Evasion of the Epidemic Healthcare-Associated MRSA ST239. Front Microbiol. 2016;7:951doi: 10.3389/fmicb.2016.00951.
Hong, X., Qin, J., Li, T., Dai, Y., Wang, Y., Liu, Q., He, L., Lu, H., Gao, Q., Lin, Y., & Li, M. (2016). Staphylococcal Protein A Promotes Colonization and Immune Evasion of the Epidemic Healthcare-Associated MRSA ST239. Frontiers in microbiology, 7951. https://doi.org/10.3389/fmicb.2016.00951
Hong, Xufen, et al. "Staphylococcal Protein A Promotes Colonization and Immune Evasion of the Epidemic Healthcare-Associated MRSA ST239." Frontiers in microbiology vol. 7 (2016): 951. doi: https://doi.org/10.3389/fmicb.2016.00951
Hong X, Qin J, Li T, Dai Y, Wang Y, Liu Q, He L, Lu H, Gao Q, Lin Y, Li M. Staphylococcal Protein A Promotes Colonization and Immune Evasion of the Epidemic Healthcare-Associated MRSA ST239. Front Microbiol. 2016 Jun 27;7:951. doi: 10.3389/fmicb.2016.00951. eCollection 2016. PMID: 27446000; PMCID: PMC4922140.
Copy Download .nbib Format: NLM
Share it on

Front Microbiol. 2016 Jun 27;7:951. doi: 10.3389/fmicb.2016.00951. eCollection 2016.

Staphylococcal Protein A Promotes Colonization and Immune Evasion of the Epidemic Healthcare-Associated MRSA ST239.

Frontiers in microbiology

Xufen Hong, Juanxiu Qin, Tianming Li, Yingxin Dai, Yanan Wang, Qian Liu, Lei He, Huiying Lu, Qianqian Gao, Yong Lin, Min Li

Affiliations

  1. Department of Laboratory Medicine, Huashan Hospital, Shanghai Medical College, Fudan University Shanghai, China.
  2. Department of Laboratory Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai, China.

PMID: 27446000 PMCID: PMC4922140 DOI: 10.3389/fmicb.2016.00951

Abstract

The highly successful epidemic of healthcare-associated methicillin-resistant Staphylococcus aureus (HA-MRSA) ST239 is a growing concern worldwide, due to its progressive adaptation to the highly selective environment of the healthcare system. HA-MRSA ST239 display the reduced virulence and successfully colonize in hospital settings, while the emergent community-associated MRSA (CA-MRSA) maintain full virulence and cause infections in the community environment. Our aim was to investigate what enables S. aureus ST239 to be highly adaptive under hospital circumstances and gradually progress to a series of widespread invasive infections. We found that spa expression of HA-MRSA ST239 is much higher than that of CA-SA ST398. And we discovered that the highly production of staphylococcal protein A (SpA), having no concern with spa gene structure, enhances nasal colonization and cell adhesion in ST239. S. aureus ST239 defends against the adaptive immune response by resisting phagocytosis and inducing apoptosis of B cells through expression of surface-anchored and released protein A, facilitating its dissemination within the circulatory system to other organs. Protein A also plays another key role in subverting the host immune response through its ability to induce early shedding of TNF-α receptor 1 (TNFR1) from phagocytic cells. The increased levels of soluble TNFR1 present during experimental S. aureus ST239 infection may neutralize circulating TNF-α and impair the host inflammatory response. Protein A is also a virulence factor, as tested in our bacteremia model in mice, contributing to the durative tissue damage of abscess formation sites in ST239 infection. These functions of protein A eventually benefit to widespread infections of S. aureus ST239. We draw the conclusion that Staphylococcal Protein A may be a crucial determinant in the colonization and immune evasion of ST239 infections, contributing to persistent spread in the hospital settings. These results suggest that antibodies against protein A may provide insights into the development of novel treatments against S. aureus, especially HA-MRSA.

Keywords: adhesion; colonization; healthcare-associated methicillin-resistant Staphylococcus aureus; immune evasion; protein A

References

  1. FASEB J. 2009 Oct;23(10):3393-404 - PubMed
  2. Proc Natl Acad Sci U S A. 2014 Jan 28;111(4):1574-9 - PubMed
  3. Ann Clin Microbiol Antimicrob. 2006 Nov 10;5:26 - PubMed
  4. J Antimicrob Chemother. 1988 Apr;21 Suppl C:57-65 - PubMed
  5. Infect Genet Evol. 2015 Apr;31:9-16 - PubMed
  6. Nat Med. 2004 Aug;10(8):842-8 - PubMed
  7. J Proteome Res. 2011 Apr 1;10(4):2064-78 - PubMed
  8. J Immunol. 1998 Dec 1;161(11):5937-42 - PubMed
  9. J Infect Dis. 2012 Mar 1;205(5):798-806 - PubMed
  10. PLoS One. 2012;7(6):e38577 - PubMed
  11. EMBO J. 2007 Feb 7;26(3):701-9 - PubMed
  12. Trends Microbiol. 2005 Dec;13(12):596-601 - PubMed
  13. Trends Microbiol. 2012 May;20(5):243-50 - PubMed
  14. FASEB J. 2011 Oct;25(10):3605-12 - PubMed
  15. J Infect Dis. 2011 Aug 1;204(3):348-57 - PubMed
  16. Nature. 1983 Oct 20-26;305(5936):709-12 - PubMed
  17. Science. 2010 Jan 22;327(5964):469-74 - PubMed
  18. Nat Med. 2012 May;18(5):816-9 - PubMed
  19. Nat Rev Microbiol. 2015 Sep;13(9):529-43 - PubMed
  20. Antimicrob Agents Chemother. 2009 Feb;53(2):512-8 - PubMed
  21. PLoS One. 2010 Apr 06;5(4):e10040 - PubMed
  22. J Exp Med. 2003 May 5;197(9):1125-39 - PubMed
  23. Arch Dermatol. 1986 Feb;122(2):166-9 - PubMed
  24. J Clin Microbiol. 2013 Nov;51(11):3638-44 - PubMed
  25. Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3140-5 - PubMed
  26. JAMA Intern Med. 2013 Nov 25;173(21):1970-8 - PubMed
  27. Drug Resist Updat. 2011 Aug-Oct;14(4-5):236-50 - PubMed
  28. Infect Immun. 2013 Nov;81(11):4200-7 - PubMed
  29. J Invest Dermatol. 1998 Sep;111(3):452-6 - PubMed
  30. PLoS Pathog. 2011 Feb 03;7(2):e1001267 - PubMed
  31. PLoS Pathog. 2009 Jul;5(7):e1000533 - PubMed
  32. J Med Microbiol. 2001 Jan;50(1):35-41 - PubMed
  33. Plasmid. 2006 Jan;55(1):58-63 - PubMed
  34. J Exp Med. 2014 Nov 17;211(12):2331-9 - PubMed
  35. Microb Pathog. 2002 Nov;33(5):239-49 - PubMed
  36. Nat Med. 2004 Mar;10(3):243-5 - PubMed
  37. Future Microbiol. 2009 Dec;4(10):1337-52 - PubMed
  38. MBio. 2015 Mar 03;6(2):e00080 - PubMed
  39. Antimicrob Agents Chemother. 2010 May;54(5):1842-7 - PubMed
  40. Clin Microbiol Infect. 2014 Jul;20(7):605-23 - PubMed
  41. J Infect Dis. 2015 Oct 15;212(8):1308-16 - PubMed
  42. BMC Microbiol. 2013 Jul 08;13:153 - PubMed
  43. J Immunol. 2004 Jan 15;172(2):1169-76 - PubMed
  44. J Antimicrob Chemother. 2008 May;61(5):976-94 - PubMed
  45. FEMS Immunol Med Microbiol. 2010 Apr;58(3):356-62 - PubMed
  46. J Gen Microbiol. 1992 Jan;138(1):169-80 - PubMed
  47. Trends Microbiol. 2003 Dec;11(12):554-61 - PubMed
  48. MBio. 2013 Aug 27;4(5):e00575-13 - PubMed
  49. Infect Immun. 2012 Oct;80(10):3460-70 - PubMed
  50. PLoS Med. 2008 Jan 15;5(1):e17 - PubMed
  51. Infect Immun. 1977 Mar;15(3):760-4 - PubMed
  52. FEMS Microbiol Rev. 2015 Sep;39(5):750-63 - PubMed
  53. Infect Immun. 1995 Apr;63(4):1165-72 - PubMed
  54. Proc Natl Acad Sci U S A. 2000 May 9;97(10):5399-404 - PubMed
  55. Gene. 1991 Jul 15;103(1):101-5 - PubMed
  56. J Exp Med. 2010 Aug 30;207(9):1863-70 - PubMed
  57. J Clin Microbiol. 2004 Feb;42(2):792-9 - PubMed
  58. Biochemistry. 1981 Apr 28;20(9):2361-70 - PubMed
  59. Cell Host Microbe. 2007 May 17;1(3):199-212 - PubMed
  60. BMC Microbiol. 2009 Jan 30;9:22 - PubMed
  61. Emerg Infect Dis. 2008 Mar;14(3):479-83 - PubMed
  62. Clin Infect Dis. 2004 Sep 15;39(6):776-82 - PubMed
  63. J Neuropathol Exp Neurol. 2004 Apr;63(4):381-96 - PubMed
  64. J Clin Microbiol. 2003 Jan;41(1):159-63 - PubMed
  65. Lancet. 2004 Aug 21-27;364(9435):703-5 - PubMed

Publication Types